Anti-EHV-1 glycoprotein B/gB Polyclonal Antibody
Biological Function:
The Anti-EHV-1 glycoprotein B/gB Polyclonal Antibody is a powerful tool for detecting and studying the glycoprotein B (gB) of Equine Herpesvirus 1 (EHV-1). This glycoprotein is essential for the virus to enter and infect host cells, making it a crucial target for research and diagnostic purposes.
Main Applications:
This antibody is specifically designed to recognize and bind to the gB protein of EHV-1, making it an ideal tool for various applications. It can be used for the detection and quantification of EHV-1 infection in equine samples, as well as for studying the virus’s molecular mechanisms and host-virus interactions.
Experimental Use Cases:
The Anti-EHV-1 glycoprotein B/gB Polyclonal Antibody has been extensively tested and validated for use in various experimental settings. It has been successfully used in Western blot, immunofluorescence, and ELISA assays, providing reliable and accurate results.
In addition, this antibody has shown promising results in neutralization assays, where it has been used to block the interaction between gB and its cellular receptors, inhibiting the virus’s entry into host cells. This makes it a valuable tool for developing antiviral therapies against EHV-1.
This polyclonal antibody is a highly specific and sensitive reagent for detecting and studying the gB protein of EHV-1. Its exceptional performance in various experimental techniques makes it an essential tool for researchers and diagnosticians working with this virus.
Structure:
Discover the Power of Anti-EHV-1 gB Polyclonal Antibody
Biological Function
Main Applications
Experimental Use Cases
In summary, the Anti-EHV-1 glycoprotein B/gB Polyclonal Antibody is a reliable and efficient tool for studying and detecting EHV-1 infection. Its specificity, sensitivity, and versatility make it a valuable asset for researchers and diagnosticians in the biotech industry. Order now and unlock the potential of this powerful antibody for your research.
There are no reviews yet.